| 2.92 1.22 (71.76%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.97 |
1-year : | 4.63 |
| Resists | First : | 3.4 |
Second : | 3.97 |
| Pivot price | 2 |
|||
| Supports | First : | 2.34 |
Second : | 1.7 |
| MAs | MA(5) : | 1.99 |
MA(20) : | 2.01 |
| MA(100) : | 2.5 |
MA(250) : | 2.63  |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 25.8 |
D(3) : | 11.3 |
| RSI | RSI(14): 73.2 |
|||
| 52-week | High : | 21.95 | Low : | 1.4 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VIVS ] has closed Bollinger Bands are 15.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.4 - 3.42 | 3.42 - 3.44 |
| Low: | 2.6 - 2.62 | 2.62 - 2.64 |
| Close: | 2.99 - 3.02 | 3.02 - 3.05 |
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California.
Sun, 01 Feb 2026
VivoSim Labs Leaps 82% Amid Strategic Partnerships in Asia - StocksToTrade
Sat, 31 Jan 2026
VivoSim Labs Shares Surge 82% Amid Key Asia Distribution Deals - StocksToTrade
Sat, 31 Jan 2026
VivoSim Labs Stock Soars After Major Distribution Deals in Asia - timothysykes.com
Fri, 30 Jan 2026
VivoSim Labs, Inc. - Common Stock (NQ: VIVS - The Chronicle-Journal
Fri, 30 Jan 2026
VivoSim Labs Expands Amid Global Market Challenges - StocksToTrade
Fri, 30 Jan 2026
VivoSim Labs stock (VIVS) jumps premarket after Korea, China distributor deals — what to watch next - TechStock²
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 2.58e+006 (%) |
| Held by Institutions | 1 (%) |
| Shares Short | 38 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.192e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 410.7 % |
| Return on Equity (ttm) | -92.6 % |
| Qtrly Rev. Growth | 140000 % |
| Gross Profit (p.s.) | -5.68 |
| Sales Per Share | -31.28 |
| EBITDA (p.s.) | -3.74576e+006 |
| Qtrly Earnings Growth | 0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.1 |
| Price to Cash Flow | 1.31 |
| Dividend | 0 |
| Forward Dividend | 11110 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|